

Xinmeng Jasmine Mu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10556593/xinmeng-jasmine-mu-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

6,737
citations

19
h-index

23
g-index

23
ext. papers

8,345
ext. citations

25.8
avg, IF

4.45
L-index

#	Paper	IF	Citations
22	An integrated map of structural variation in 2,504 human genomes. <i>Nature</i> , 2015 , 526, 75-81	50.4	1368
21	Architecture of the human regulatory network derived from ENCODE data. <i>Nature</i> , 2012 , 489, 91-100	50.4	1104
20	A systematic survey of loss-of-function variants in human protein-coding genes. <i>Science</i> , 2012 , 335, 823-833	33.3	880
19	Mapping copy number variation by population-scale genome sequencing. <i>Nature</i> , 2011 , 470, 59-65	50.4	833
18	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. <i>Cell Reports</i> , 2016 , 15, 857-865	10.6	422
17	RNF43 is frequently mutated in colorectal and endometrial cancers. <i>Nature Genetics</i> , 2014 , 46, 1264-6	36.3	287
16	Integrative annotation of variants from 1092 humans: application to cancer genomics. <i>Science</i> , 2013 , 342, 1235-1237	33.3	281
15	The real cost of sequencing: higher than you think!. <i>Genome Biology</i> , 2011 , 12, 125	18.3	247
14	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. <i>Cancer Discovery</i> , 2018 , 8, 730-749	24.4	235
13	FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. <i>Genome Biology</i> , 2014 , 15, 480	18.3	209
12	PEMer: a computational framework with simulation-based error models for inferring genomic structural variants from massive paired-end sequencing data. <i>Genome Biology</i> , 2009 , 10, R23	18.3	201
11	Nucleotide-resolution analysis of structural variants using BreakSeq and a breakpoint library. <i>Nature Biotechnology</i> , 2010 , 28, 47-55	44.5	136
10	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020 , 26, 1733-1741	50.5	85
9	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 101-101	2.2	59
8	Analysis of genomic variation in non-coding elements using population-scale sequencing data from the 1000 Genomes Project. <i>Nucleic Acids Research</i> , 2011 , 39, 7058-76	20.1	58
7	Analysis of deletion breakpoints from 1,092 humans reveals details of mutation mechanisms. <i>Nature Communications</i> , 2015 , 6, 7256	17.4	56
6	Inherited DNA-Repair Defects in Colorectal Cancer. <i>American Journal of Human Genetics</i> , 2018 , 102, 401-414	41.4	50

5	TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. <i>Oncolmmunology</i> , 2018 , 7, e1442999 ^{7.2}	36
4	Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. <i>Nature Communications</i> , 2020 , 11, 3644	17.4 16
3	Standard machine learning approaches outperform deep representation learning on phenotype prediction from transcriptomics data. <i>BMC Bioinformatics</i> , 2020 , 21, 119	3.6 14
2	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.. <i>Lancet Oncology, The</i> , 2021 ,	21.7 8
1	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. <i>Nature Medicine</i> , 2021 ,	50.5 6